Breast lumps screening

Jump to navigation Jump to search

Breast lumps Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Breast lumps from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Breast lumps screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Breast lumps screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Breast lumps screening

on Breast lumps screening

Breast lumps screening in the news

Blogs on Breast lumps screening

Directions to Hospitals Treating Breast lumps

Risk calculators and risk factors for Breast lumps screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

The Screening methods of breast lesions[1]:

  • Breast examination
  • Breast ultrasound
    • whole breast ultrasound detects lesions in dense breast tissue which could not be diagnosed by mammography [2]
  • Mammography
    • Gold standard of screening
    • Early detection of non-palpabale masses
    • Regarding to 2013 NCCN guidelines annual screening in average risk women aged≥ 40 years
    • Regarding to 2013 NCCN guidelines annual screening in high risk women from age of 25 years
    • Sensitivity of 0.33-0.39 and specificity of 0.95
  • Magnetic resonance imaging (MRI)
    • Significant method for detection, assessment and management of breast cancer
    • Sensitivity of 0.77-0.79 and specificity of 0.86-0.89
    • Based on 2013 NCCN guidelines annual MRI for individuals with > 20% risk of developing breast cancer in lifetime starting at age of 25 years
    • Beneficial modality in high risk individuals
    • Valuable in individuals with equivocal results from other screening tests
    • Usable for individuals with ineffective mammography results due to breast augmentation

References

  1. Shah R, Rosso K, Nathanson SD (2014). "Pathogenesis, prevention, diagnosis and treatment of breast cancer". World J Clin Oncol. 5 (3): 283–98. doi:10.5306/wjco.v5.i3.283. PMC 4127601. PMID 25114845.
  2. Kelly KM, Dean J, Comulada WS, Lee SJ (2010). "Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts". Eur Radiol. 20 (3): 734–42. doi:10.1007/s00330-009-1588-y. PMC 2822222. PMID 19727744.

Template:WH Template:WS